ArticleNature communications2020
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.Journal of applied biomedicine · 2024Pooled it
- Article
- BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Toward a chemotherapy and allo-HSCT free future: the evolution of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia.Frontiers in immunology · 2026Review
- Beyond FOXO1: AS1842856 inhibits GSK3 to enhance cytotoxic effects in B-ALL.Blood advances · 2025Article
- Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure.HemaSphere · 2025Article
- Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation.Discover oncology · 2024Article
- An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2024Article
- Article
- Influence of bariatric surgery on the peripheral blood immune system of female patients with morbid obesity revealed by high-dimensional mass cytometry.Frontiers in immunology · 2023Article
- CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia.Oncogenesis · 2022Article
- Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.Leukemia · 2022Article
- The Small GTPase RHOA Links SLP65 Activation to PTEN Function in Pre B Cells and Is Essential for the Generation and Survival of Normal and Malignant B Cells.Frontiers in immunology · 2022Article
- An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.Acta pharmaceutica Sinica. B · 2021Article
- The Emerging Role of Suppressors of Cytokine Signaling (SOCS) in the Development and Progression of Leukemia.Cancers · 2021Review
- Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 3 countries.
Hend AbdelrasoulInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Anila VadakumcheryInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Markus WernerInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Lennart LenkDepartment of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Ahmad KhadourInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Marc YoungInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Omar El AyoubiInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Fotini VogiatziDepartment of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Markus KrämerInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Vera SchmidInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.ORCID http://orcid.org/0000-0002-6035-2265
Zhengshan ChenDepartment of Systems Biology and City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
Yasar YousafzaiInstitute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Gunnar CarioDepartment of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Martin SchrappeDepartment of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Markus MüschenDepartment of Systems Biology and City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.ORCID http://orcid.org/0000-0002-6064-8613
Christina HalseyInstitute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0001-5449-5246
Medhanie A MulawInstitute of Experimental Cancer Research, Medical Faculty, University of Ulm, Ulm, Germany.ORCID http://orcid.org/0000-0002-2501-6952
Denis M ScheweDepartment of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0002-1070-0217
Elias HobeikaInstitute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.
Ameera Alsadeq *Institute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany.ORCID http://orcid.org/0000-0003-0568-9890
Hassan Jumaa *Institute of Immunology, Ulm University Medical Center, 89081, Ulm, Germany. hassan.jumaa@uni-ulm.de.ORCID http://orcid.org/0000-0003-3383-141X
Universität Ulm · DEChristian-Albrechts-Universität zu Kiel · DECity of Hope · USUniversity of Glasgow · GB
Funding
Metabolic gatekeepers in B-cell malignanciesR35CA197628 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2016 to 2026
$11.7MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MCD25-mediated feedback control of BCR-signaling and its oncogenic mimicsR01CA213138 · NCI · YALE UNIVERSITY · PI MÜSCHEN, MARKUS · 2017 to 2022
$1.9MChief Scientist Office ETM/374Howard Hughes Medical InstituteNCI NIH HHS R01 CA157644NCI NIH HHS R01 CA213138NCI NIH HHS R35 CA197628
Abstract
Ph
Indexed as
Philadelphia ChromosomeAnimalsCell Line, TumorCell Transformation, NeoplasticFemaleForkhead Box Protein O1Fusion Proteins, bcr-ablGene Expression Regulation, NeoplasticHumansInterleukin-7Interleukin-7 Receptor alpha SubunitMiceMice, Mutant StrainsPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsReceptors, CXCR4CXCR4 protein, humanForkhead Box Protein O1FOXO1 protein, humanFusion Proteins, bcr-ablIL7R protein, humanInterleukin-7Interleukin-7 Receptor alpha SubunitProtein Kinase InhibitorsReceptors, CXCR4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.